Diabetes Decline Continues On Schedule At Sanofi
This article was originally published in Scrip
"The good news is that there is no news," said Sanofi's CEO Olivier Brandicourt, commenting on the company's diabetes franchise during its 2015 annual results presentation on Feb 9. "We delivered exactly what we said we would." Sanofi managed this by offsetting worse than expected Lantus sales with a better than expected performance by its newer insulin glargine injection, Toujeo.
You may also be interested in...
Sanofi clearly would benefit from its proposed $9.3bn purchase of Medivation Inc. based on the French company's first quarter earnings, which show a pharmaceuticals business that's suffering from competition, US drug pricing pressures and foreign currency exchange issues.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.